{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:12:46Z","timestamp":1763035966548,"version":"build-2065373602"},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,10,12]],"date-time":"2004-10-12T00:00:00Z","timestamp":1097539200000},"content-version":"vor","delay-in-days":4302,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1993,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X\u2010linked dystonia with parkinsonism, painful legs and moving toes, and stiff\u2010person syndrome. Milacemide was initiated at a dose of 2,400 mg\/ day, orally, and increased gradually to a maximum of 4,800 mg\/ day. No clear\u2010cut observable improvement occurred. There were no serious adverse effects.<\/jats:p>","DOI":"10.1002\/mds.870080412","type":"journal-article","created":{"date-parts":[[2004,12,31]],"date-time":"2004-12-31T10:07:21Z","timestamp":1104487641000},"page":"484-488","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders"],"prefix":"10.1002","volume":"8","author":[{"given":"Mark Forrest","family":"Gordon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando","family":"Diaz\u2010Olivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann L.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley","family":"Fahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,12]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"1","article-title":"Definition and clinical classification of myoclonus","volume":"43","author":"Fahn S","year":"1986","journal-title":"Adv Neruol"},{"doi-asserted-by":"publisher","key":"e_1_2_1_3_2","DOI":"10.1016\/0014-4886(84)90140-7"},{"doi-asserted-by":"publisher","key":"e_1_2_1_4_2","DOI":"10.1016\/0024-3205(85)90490-4"},{"doi-asserted-by":"publisher","key":"e_1_2_1_5_2","DOI":"10.1016\/0014-2999(74)90091-0"},{"doi-asserted-by":"publisher","key":"e_1_2_1_6_2","DOI":"10.1002\/mds.870030110"},{"key":"e_1_2_1_7_2","first-page":"149","article-title":"Intracerebroventricular glycine blocks myoclonus induced by p, p'\u2010DDT in the rat","volume":"20","author":"Truong DD","year":"1986","journal-title":"Ann Neurol"},{"doi-asserted-by":"publisher","key":"e_1_2_1_8_2","DOI":"10.1002\/mds.870030306"},{"doi-asserted-by":"publisher","key":"e_1_2_1_9_2","DOI":"10.1152\/ajplegacy.1971.221.6.1629"},{"doi-asserted-by":"publisher","key":"e_1_2_1_10_2","DOI":"10.1016\/0024-3205(83)90127-3"},{"unstructured":"Milacemide (CP 1552 S) investigational brochure. Skokie IL. Searle 1987 Document EC7\u201087\u201001\u2010900.","key":"e_1_2_1_11_2"},{"issue":"1","key":"e_1_2_1_12_2","first-page":"377","article-title":"DDT\u2010induced myoclonus in rats: effects of therapeutic agents","volume":"37","author":"Truong DD","year":"1987","journal-title":"Neurology"},{"doi-asserted-by":"publisher","key":"e_1_2_1_13_2","DOI":"10.1016\/0024-3205(89)90558-4"},{"doi-asserted-by":"publisher","key":"e_1_2_1_14_2","DOI":"10.1016\/0091-3057(89)90072-5"},{"doi-asserted-by":"publisher","key":"e_1_2_1_15_2","DOI":"10.1111\/j.1471-4159.1989.tb07403.x"},{"doi-asserted-by":"publisher","key":"e_1_2_1_16_2","DOI":"10.1111\/j.1528-1157.1986.tb03537.x"},{"doi-asserted-by":"publisher","key":"e_1_2_1_17_2","DOI":"10.1002\/mds.870060114"},{"key":"e_1_2_1_18_2","first-page":"383","article-title":"Segmental tremor vs. rhythmic myoclonus: successful treatment with serotonin precursors","volume":"30","author":"Fahn S","year":"1980","journal-title":"Neurology"},{"key":"e_1_2_1_19_2","first-page":"49","article-title":"Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen","volume":"26","author":"Fahn S.","year":"1979","journal-title":"Adv Neurol"},{"key":"e_1_2_1_20_2","first-page":"197","article-title":"Newer drugs for posthypoxis action myoclonus: observations from a well\u2010studied case","volume":"43","author":"Fahn S.","year":"1986","journal-title":"Adv Neurol"},{"key":"e_1_2_1_21_2","first-page":"80","article-title":"An oscillating form of essential myoclonus","volume":"31","author":"Fahn S","year":"1981","journal-title":"Neurology"},{"key":"e_1_2_1_22_2","first-page":"171","article-title":"Biochemistry and therapeutics of posthypoxic myoclonus","volume":"43","author":"Van Woert MH","year":"1986","journal-title":"Adv Neurol"},{"doi-asserted-by":"publisher","key":"e_1_2_1_23_2","DOI":"10.1093\/brain\/100.3.455"},{"key":"e_1_2_1_24_2","first-page":"741","article-title":"Measurement of GABA in biological fluids: effect of GABA transaminase inhibitors","volume":"23","author":"Enna SJ","year":"1979","journal-title":"Adv Neurol"},{"doi-asserted-by":"publisher","key":"e_1_2_1_25_2","DOI":"10.1097\/00002826-198303000-00005"},{"key":"e_1_2_1_26_2","first-page":"713","article-title":"Anticonvulsant drugs: mechanisms of action","volume":"44","author":"Macdonald RL","year":"1986","journal-title":"Adv Neurol"},{"doi-asserted-by":"publisher","key":"e_1_2_1_27_2","DOI":"10.1126\/science.164.3879.571"},{"doi-asserted-by":"publisher","key":"e_1_2_1_28_2","DOI":"10.1016\/0024-3205(70)90081-0"},{"doi-asserted-by":"publisher","key":"e_1_2_1_29_2","DOI":"10.1212\/WNL.25.7.622"},{"doi-asserted-by":"publisher","key":"e_1_2_1_30_2","DOI":"10.1007\/BF00312924"},{"key":"e_1_2_1_31_2","first-page":"203","article-title":"A new and effective drug in the treatment of stiff\u2010man syndrome: preliminary report","volume":"38","author":"Howard FM","year":"1963","journal-title":"Mayo Clin Proc"},{"doi-asserted-by":"publisher","key":"e_1_2_1_32_2","DOI":"10.1212\/WNL.31.9.1162"},{"key":"e_1_2_1_33_2","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jama.1977.03270450020010","article-title":"Stiff\u2010man syndrome and clonazepam","volume":"237","author":"Westblom U.","year":"1977","journal-title":"JAMA"},{"doi-asserted-by":"publisher","key":"e_1_2_1_34_2","DOI":"10.1002\/ana.410090516"},{"doi-asserted-by":"publisher","key":"e_1_2_1_35_2","DOI":"10.1001\/archneur.1980.00500580096024"},{"doi-asserted-by":"publisher","key":"e_1_2_1_36_2","DOI":"10.1056\/NEJM198804213181602"},{"doi-asserted-by":"publisher","key":"e_1_2_1_37_2","DOI":"10.1056\/NEJM199005313222202"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870080412","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870080412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:23:31Z","timestamp":1760959411000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870080412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,1]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1993,1]]}},"alternative-id":["10.1002\/mds.870080412"],"URL":"https:\/\/doi.org\/10.1002\/mds.870080412","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[1993,1]]}}}